243972-26-1

Basic information

• Product Name: 2-Amino-5-(tributylstannyl)-1,3-thiazole, N-BOC protected
• Synonyms: 2-Amino-5-(tributylstannyl)-1,3-thiazole, N-BOC protected;[5-(TRIBUTYLSTANNYL)THIAZOL-2-YL]CARBAMIC ACID TERT-BUTYL ESTER;2-Amino-5-(tributylstannyl)-1,3-thiazole, 2-BOC protected;{2-[(tert-Butoxycarbonyl)amino]-1,3-thiazol-5-yl}tributylstannane, tert-Butyl [5-(tributylstannyl)-1,3-thiazol-2-yl]carbamate;2-AMino-5-(tributylstannyl)-1,3-thiazole;2-(N-Boc-amino)-5-(tributylstannyl)thiazole
• CAS NO: 243972-26-1
• Molecular Formula: C₂₀H₃₈N₂O₂SSn
• Molecular Weight: 489.29
• Product Categories: Stannanes;organic tin
• Mol File: 243972-26-1.mol
• Article Data: 5

Chemical Properties

• Melting Point: 78-86°C
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.24±0.70(Predicted)
• CAS DataBase Reference: 2-Amino-5-(tributylstannyl)-1,3-thiazole, N-BOC protected(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-(tributylstannyl)-1,3-thiazole, N-BOC protected(243972-26-1)
• EPA Substance Registry System: 2-Amino-5-(tributylstannyl)-1,3-thiazole, N-BOC protected(243972-26-1)

Safety Data

• Hazard Codes: T,N
• Statements: 21-25-36/38-48/23/25-50/53
• Safety Statements: 36/37/39-45-60-61
• RIDADR: UN 3146 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 243972-26-1(Hazardous Substances Data)

Usage

General Description

2-Amino-5-(tributylstannyl)-1,3-thiazole, N-BOC protected is a chemical compound that consists of a thiazole ring with an amino group and a tributylstannyl moiety. The N-BOC protection refers to the presence of a tert-butoxycarbonyl group on the amino group, which serves to protect it from unwanted reactions. 2-Amino-5-(tributylstannyl)-1,3-thiazole, N-BOC protected is commonly used in organic synthesis as a building block for the preparation of more complex molecules. Its tributylstannyl group allows for selective reactions with other organic compounds, while the N-BOC protection ensures the stability of the amino group during these reactions. Overall, this compound is a valuable tool for the creation of diverse chemical structures in the laboratory.

InChI:InChI=1/C8H11N2O2S.3C4H9.Sn/c1-8(2,3)12-7(11)10-6-9-4-5-13-6;3*1-3-4-2;/h4H,1-3H3,(H,9,10,11);3*1,3-4H2,2H3;/rC20H38N2O2SSn/c1-7-10-13-26(14-11-8-2,15-12-9-3)17-16-21-18(25-17)22-19(23)24-20(4,5)6/h16H,7-15H2,1-6H3,(H,21,22,23)

Upstream product

• 1461-22-9 tributyltin chloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 170961-15-6 tert-butyl 1,3-thiazole-2-yl-carbamate 

Downstream Products

• 1542268-37-0 C₂₅H₃₁N₇O₅S 
• 1542268-01-8 C₂₇H₂₈N₆O₄S₂ 
• 1542268-21-2 C₂₅H₃₀FN₇O₅S 
• 1542268-02-9 C₂₇H₂₈N₆O₆S₂ 
• 1542268-03-0 C₂₅H₃₁N₇O₅S 
• 1391926-40-1 tert-butyl (5-(4-(4-(dimethylcarbamoyl)phenoxy)-6-morpholino-1,3,5-triazin-2-yl)thiazol-2-yl)carbamate 

Relevant articles and documents

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway

FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE

The invention relates to thiazole compounds of Formula (I) and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.